| pubmed-article:9398710 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0001455 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0020437 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:9398710 | lifeskim:mentions | umls-concept:C0370232 | lld:lifeskim |
| pubmed-article:9398710 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:9398710 | pubmed:dateCreated | 1998-1-13 | lld:pubmed |
| pubmed-article:9398710 | pubmed:abstractText | The treatment of cancer patients with conventional chemotherapy is sometimes associated with severe systemic toxicity and only a minimal survival benefit. Because of this, new less toxic and more efficacious treatments have been sought. 8-Chloro-cAMP (8-Cl-cAMP) is one of a new generation of anticancer drugs that act at the level of signal transduction. In preclinical models, 8-Cl-cAMP modulates protein kinase A (PKA) leading to growth inhibition and increased differentiation of cancer cells. 8-Cl-cAMP was given to 16 patients with advanced cancer as an infusion via an indwelling subclavian venous catheter. We showed that 8-Cl-cAMP had a parathyroid hormone-like effect leading to increased synthesis of renal 1,25-dihydroxyvitamin D [up to 14 times the baseline value, median 3.6 times; P = 0.00001 (Student's paired t test)]. This produced the dose-limiting toxicity of reversible hypercalcemia that could not be controlled by the administration of either pamidronate or dexamethasone. The treatment was otherwise well tolerated, and other cAMP-dependent pathways (cortisol and TSH) were not affected, emphasizing the marked differences between organs in their sensitivity to this cAMP analog. Our results have shown that 8-Cl-cAMP is biologically active, and it is feasible that if the hypercalcemia can be controlled, then this drug may have a role as a single agent, or as a short infusion between cycles of chemotherapy. | lld:pubmed |
| pubmed-article:9398710 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9398710 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9398710 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9398710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9398710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9398710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9398710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9398710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9398710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9398710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9398710 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9398710 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:9398710 | pubmed:issn | 0021-972X | lld:pubmed |
| pubmed-article:9398710 | pubmed:author | pubmed-author:HarrisA LAL | lld:pubmed |
| pubmed-article:9398710 | pubmed:author | pubmed-author:MawerE BEB | lld:pubmed |
| pubmed-article:9398710 | pubmed:author | pubmed-author:LonaFF | lld:pubmed |
| pubmed-article:9398710 | pubmed:author | pubmed-author:TalbotD CDC | lld:pubmed |
| pubmed-article:9398710 | pubmed:author | pubmed-author:SalisburyA... | lld:pubmed |
| pubmed-article:9398710 | pubmed:author | pubmed-author:SaundersM PMP | lld:pubmed |
| pubmed-article:9398710 | pubmed:author | pubmed-author:O'ByrneK JKJ | lld:pubmed |
| pubmed-article:9398710 | pubmed:author | pubmed-author:WhitehouseR... | lld:pubmed |
| pubmed-article:9398710 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9398710 | pubmed:volume | 82 | lld:pubmed |
| pubmed-article:9398710 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9398710 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9398710 | pubmed:pagination | 4044-8 | lld:pubmed |
| pubmed-article:9398710 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:meshHeading | pubmed-meshheading:9398710-... | lld:pubmed |
| pubmed-article:9398710 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9398710 | pubmed:articleTitle | A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumors. | lld:pubmed |
| pubmed-article:9398710 | pubmed:affiliation | Imperial Cancer Research Fund, Medical Oncology Unit, Churchill Hospital, Oxford, United Kingdom. | lld:pubmed |
| pubmed-article:9398710 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9398710 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9398710 | lld:pubmed |
